EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Articles|June 1, 2007
Picture Gallery of Fungal Infections in Elderly
Author(s)Noah S. Scheinfeld, MD, JD
A fungal folliculitis (Majocchi granulomas) can occur if a superficial fungal infection is treated with topical corticosteroids. Fungal folliculitis is best treated with a short course of oral itraconazole or fluconazole.
Advertisement
Figure –
Fungal folliculitis (Majocchi granulomas) developed after a topical corticosteroid was applied to treat a presumed contact dermatitis, which was actually tinea pedis.
Fungal Folliculitis
A fungal folliculitis (Majocchi granulomas) (Figure) can occur if a superficial fungal infection is treated with topical corticosteroids. Fungal folliculitis is best treated with a short course of oral itraconazole or fluconazole.
References:
FOR MORE INFORMATION:
- Brodell RT, Elewski B. Superficial fungal infections. Errors to avoid in diagnosis and treatment. Postgrad Med. 1997;101(4):279-287.
- Loo DS. Onychomycosis in the elderly: drug treatment options. Drugs Aging. 2007;24:293-302.
- Tan JS, Joseph WS. Common fungal infections of the feet in patients with diabetes mellitus. Drugs Aging. 2004;21;101-112.
- Weinberg JM, Scheinfeld NS. Cutaneous infections in the elderly: diagnosis and management. Dermatol Ther. 2003;16:195-205.
- Weinberg JM, Vafaie J, Scheinfeld NS. Skin infections in the elderly. Dermatol Clin. 2004;22:51-61.
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
Advertisement
Advertisement
Trending on Patient Care Online
1
Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months in New Study
2
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
3
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
4
Long-Term and Real-World Safety Data on Antipsychotic Agitation Therapy
5